Members Trust Co lessened its position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 12.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,339 shares of the company’s stock after selling 1,013 shares during the quarter. AbbVie makes up about 0.0% of Members Trust Co’s holdings, making the stock its 28th largest position. Members Trust Co’s holdings in AbbVie were worth $1,449,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. grew its holdings in shares of AbbVie by 6.2% during the first quarter. Vanguard Group Inc. now owns 170,376,746 shares of the company’s stock worth $31,025,605,000 after buying an additional 9,978,415 shares in the last quarter. Capital World Investors raised its holdings in AbbVie by 249.1% in the 1st quarter. Capital World Investors now owns 4,373,184 shares of the company’s stock valued at $796,357,000 after acquiring an additional 3,120,310 shares during the last quarter. Capital International Investors raised its holdings in AbbVie by 6.9% in the 1st quarter. Capital International Investors now owns 48,098,784 shares of the company’s stock valued at $8,758,789,000 after acquiring an additional 3,110,601 shares during the last quarter. TD Asset Management Inc boosted its holdings in shares of AbbVie by 156.0% during the first quarter. TD Asset Management Inc now owns 3,474,020 shares of the company’s stock worth $632,619,000 after purchasing an additional 2,116,997 shares during the last quarter. Finally, Swedbank AB acquired a new position in shares of AbbVie during the 1st quarter valued at about $367,372,000. 70.23% of the stock is owned by institutional investors and hedge funds.
Insider Activity at AbbVie
In other AbbVie news, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares of the company’s stock, valued at $83,299,645.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the completion of the sale, the chairman now owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 282,845 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total value of $49,497,875.00. Following the completion of the transaction, the chairman now directly owns 513,099 shares in the company, valued at approximately $89,792,325. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on ABBV
AbbVie Price Performance
Shares of ABBV stock traded down $2.76 during mid-day trading on Tuesday, hitting $191.34. 3,377,894 shares of the stock traded hands, compared to its average volume of 5,286,441. The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.71 and a current ratio of 0.81. The firm has a market cap of $337.88 billion, a price-to-earnings ratio of 58.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.63. The company’s 50-day simple moving average is $194.31 and its 200-day simple moving average is $177.47. AbbVie Inc. has a twelve month low of $135.85 and a twelve month high of $199.95.
AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.08. AbbVie had a net margin of 9.71% and a return on equity of 203.66%. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.02 billion. During the same quarter in the previous year, the business posted $2.91 earnings per share. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. As a group, equities research analysts expect that AbbVie Inc. will post 10.85 earnings per share for the current year.
AbbVie Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be issued a dividend of $1.55 per share. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.24%. AbbVie’s dividend payout ratio is currently 183.98%.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Articles
- Five stocks we like better than AbbVie
- How to Calculate Return on Investment (ROI)
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- 5 Top Rated Dividend Stocks to Consider
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.